WATERTOWN, Mass., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 12th at 3:05 p.m. Eastern Time at Le Parker Meridien Hotel in New York City.
A live audio webcast of the Wedbush presentation will be available on the company's website at http://ir.tphase.com/events.cfm. An archived presentation will be available for 90 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening MDR bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes eravacycline, a broad-spectrum intravenous and oral antibiotic that is being evaluated in phase 3 clinical trials, and two preclinical antibiotic candidates, TP-271 and TP-6076. Please visit www.tphase.com for more company information.
CONTACT: Investor Contacts: Tetraphase Pharmaceuticals Teri Dahlman 617-600-7040 email@example.com Argot Partners Susan Kim 212-600-1902 firstname.lastname@example.org Media Contact: Sam Brown Inc. Mike Beyer 312-961-2502 email@example.com